Nakamura Kazufumi, Matsubara Hiromi, Akagi Satoshi, Sarashina Toshihiro, Ejiri Kentaro, Kawakita Norifumi, Yoshida Masashi, Miyoshi Toru, Watanabe Atsuyuki, Nishii Nobuhiro, Ito Hiroshi
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
Division of Cardiology, National Hospital Organization Okayama Medical Center, Okayama 701-1192, Japan.
J Clin Med. 2017 Apr 29;6(5):48. doi: 10.3390/jcm6050048.
Nanoparticles have been used as a novel drug delivery system. Drug-incorporated nanoparticles for local delivery might optimize the efficacy and minimize the side effects of drugs. The efficacy and safety of intratracheal administration of prostacyclin analog (beraprost) -incorporated nanoparticles and imatinib (a PDGF-receptor tyrosine kinase inhibitor) -incorporated nanoparticles in Sugen-hypoxia-normoxia or monocrotaline rat models of pulmonary arterial hypertension (PAH) and in human PAH-pulmonary arterial smooth muscle cells have been reported. The use of inhaled drug-incorporated nanoparticles might be a novel approach for the treatment of PAH.
纳米颗粒已被用作一种新型药物递送系统。用于局部递送的载药纳米颗粒可能会优化药物疗效并将药物副作用降至最低。已报道了在Sugen低氧-常氧或野百合碱大鼠肺动脉高压（PAH）模型以及人PAH-肺动脉平滑肌细胞中，气管内给予载有前列环素类似物（贝拉前列素）的纳米颗粒和载有伊马替尼（一种血小板衍生生长因子受体酪氨酸激酶抑制剂）的纳米颗粒的疗效和安全性。吸入载药纳米颗粒的应用可能是治疗PAH的一种新方法。
